Nuformix plc Stock price

Equities

LVRT

GB00BYW79Y38

Pharmaceuticals

Market Closed - London S.E. 12:35:21 2024-03-28 pm EDT 5-day change 1st Jan Change
0.19 GBX 0.00% Intraday chart for Nuformix plc -5.00% -41.54%
Sales 2022 50K 63.11K Sales 2023 - Capitalization 1.94M 2.44M
Net income 2022 -1M -1.26M Net income 2023 - 0 EV / Sales 2022 41.8 x
Net cash position 2022 464K 586K Net cash position 2023 203K 256K EV / Sales 2023 -
P/E ratio 2022
-1.94 x
P/E ratio 2023
-3.27 x
Employees 3
Yield 2022 *
-
Yield 2023
-
Free-Float 84.99%
More Fundamentals * Assessed data
Dynamic Chart
1 week-5.00%
Current month-26.92%
1 month-32.14%
3 months-41.54%
6 months-28.30%
Current year-41.54%
More quotes
1 week
0.18
Extreme 0.18
0.20
1 month
0.18
Extreme 0.18
0.28
Current year
0.18
Extreme 0.18
0.44
1 year
0.18
Extreme 0.18
0.44
3 years
0.18
Extreme 0.18
2.80
5 years
0.18
Extreme 0.18
14.89
10 years
0.18
Extreme 0.18
14.89
More quotes
Managers TitleAgeSince
Founder 51 07-12-31
Corporate Secretary 47 20-12-01
Members of the board TitleAgeSince
Chairman 63 20-11-23
Director/Board Member 59 20-12-01
Founder 51 07-12-31
More insiders
Date Price Change Volume
24-03-28 0.19 0.00% 2,110,612
24-03-27 0.19 0.00% 225
24-03-26 0.19 0.00% 1,900,440
24-03-25 0.19 0.00% 1,226,656
24-03-22 0.19 -11.63% 3,733,673

Delayed Quote London S.E., March 28, 2024 at 12:35 pm EDT

More quotes
Nuformix plc is a United Kingdom-based pharmaceutical development company. The Company is engaged in targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its clinical pipeline includes NXP001, NXP002, and NXP004. NXP002 is its pre-clinical lead asset and a potential inhaled treatment for idiopathic pulmonary fibrosis (IPF) and possibly other fibrosing interstitial lung diseases (ILDs). NXP001 is a form of the drug aprepitant that is marketed as a product in the oncology supportive care setting (chemotherapy-induced nausea and vomiting). NXP004 is a form of Olaparib, which is used for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Nuformix plc - London S.E.